Milder chemo before transplant may help older blood cancer patients live longer without relapse

NCT ID NCT05436561

First seen Mar 23, 2026 · Last updated Jun 01, 2026 · Updated 4 times

Summary

This study tests a reduced-intensity chemotherapy combination (fludarabine, busulfan, melphalan) given before a stem cell transplant in people aged 55 and older with myeloid cancers like AML, MDS, or CMML. The goal is to see if this gentler approach can help patients stay free of cancer longer while reducing side effects. About 61 participants will be enrolled across multiple centers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Blood & Marrow Transplantation Center, RuiJin Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200025, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanghai No 6 Hospital

    RECRUITING

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.